Biomedicines
Plasma IgG N-Glycosylation as a Novel Biomarker of Disease Severity and Prognosis in Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
By Vibor Milunović, Maja Pučić‐Baković, Frano Vučković and 6 others.
Abstract
Background
Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous lymphoma with variable clinical outcomes despite established molecular and clinical prognostic models. Immunoglobulin G (IgG) N-glycosylation regulates antibody effector functions and reflects systemic immune status, but plasma IgG N-glycosylation has not previously been systematically investigated in DLBCL. We evaluated whether plasma IgG N-glycosylation is altered in DLBCL and examined its associations with molecular subtype, established prognostic indices, and clinical outcomes.